Sarclisa
Preclinical
SanofiSarclisa is one of 40 therapeutic programs targeting Multiple Myeloma. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
39
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
259 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1TALVEY
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Neulasta
AmgenPhase 3
Vepesid
AAvyxa
Phase 3
Cytosar
TevaPhase 3
Busulfex
Akero TherapeuticsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Sarclisa. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company